Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

STAA - STAAR Surgical Company So'nggi Yangiliklar | Finranks

Home

STAA

(STAA)

NGM – Real vaqt narxi. Valyuta: USD

17.89

-0.75 (-4.02%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

17.92

+0.03 (0.14%)

Bozordan keyin: Mar 27, 2026, 7:05 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript

STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript

STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript

Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates

Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates

Staar Surgical (STAA) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to a loss of $0.5 per share a year ago.

STAAR Surgical Issues Shareholder Letter

STAAR Surgical Issues Shareholder Letter

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interi.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases. Fourth Quarter 2025 Financial Overview.

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as.

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR S.

STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years

STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years

STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.

Videolar

No Data

There is no data to display

Press-relizlar

STAAR Surgical Issues Shareholder Letter

STAAR Surgical Issues Shareholder Letter

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interi.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases. Fourth Quarter 2025 Financial Overview.

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as.

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing.